Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.

The c-kit receptor tyrosine kinase (KIT) is constitutively activated by naturally occurring mutations in either the juxtamembrane domain or the kinase domain. Although the juxtamembrane domain mutations led to ligand-independent KIT dimerization, the kinase domain mutations (Asp814 --> Val or Tyr) did not. In an effort to determine if the kinase domain mutant could transfer oncogenic signaling without receptor dimerization, we have constructed the truncated types of c-kitWild and c-kitTyr814 cDNAs (c-kitDel-Wild and c-kitDel-Tyr814 cDNAs, respectively), in which ligand-binding and ligand-induced dimerization domains were deleted. When c-kitDel-Wild and c-kitDel-Tyr814 genes were introduced into a murine interleukin-3 (IL-3)-dependent cell line Ba/F3, KITDel-Tyr814 was constitutively phosphorylated on tyrosine and activated, whereas KITDel-Wild was not. In addition, Ba/F3 cells expressing KITDel-Tyr814 (Ba/F3(Del-Tyr814)) grew in suspension culture without the addition of exogenous growth factor, whereas Ba/F3 cells expressing KITDel-Wild (Ba/F3(Del-Wild)) required IL-3 for growth. The factor-independent growth of Ba/F3(Del-Tyr814) cells was virtually abrogated by coexpression of KITW42 that is a dominant-negative form of KIT, but not by that of KITWild, suggesting that KITDel-Tyr814 may not function as a monomer but may require receptor dimerization for inducing factor-independent growth. Furthermore, KITDel-Tyr814 was found to be coimmunoprecipitated with KITWild or KITW42 by an ACK2 monoclonal antibody directed against the extracellular domain of KIT. Moreover, KITW42 was constitutively associated with a chimeric FMS/KITTyr814 receptor containing the ligand-binding and receptor dimerization domain of c-fms receptor (FMS) fused to the transmembrane and cytoplasmic domain of KITTyr814, but not with a chimeric FMS/KITWild receptor even after stimulation with FMS-ligand. These results suggest that constitutively activating mutation of c-kit at the Asp814 codon may cause a conformation change that leads to receptor self-association not in the extracellular domain and that the receptor self-association of the Asp814 mutant may be important for activation of downstream effectors that are required for factor-independent growth and tumorigenicity.

[1]  L. Ashman,et al.  Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. , 1997, Blood.

[2]  J. Ihle,et al.  Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis , 1993, Molecular and cellular biology.

[3]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[4]  K. Davies,et al.  Molecular biology of the W and steel loci. , 1991 .

[5]  Y. Yarden,et al.  Structural aspects of receptor dimerization. c-kit as an example. , 1995, Annals of the New York Academy of Sciences.

[6]  S. Lev,et al.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Kondo,et al.  Involvement of transcription factor encoded by the mouse mi locus (MITF) in apoptosis of cultured mast cells induced by removal of interleukin-3. , 1997, The American journal of pathology.

[8]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[9]  A. Bernstein,et al.  Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1 , 1996, Nature Genetics.

[10]  H. Kitayama,et al.  Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. , 1996, The American journal of pathology.

[11]  振津 琢磨.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product , 1995 .

[12]  S. Cannistra,et al.  Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. , 1990, Blood.

[13]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[14]  H. Serve,et al.  Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. , 1994, The Journal of biological chemistry.

[15]  Y. Matsuzawa,et al.  Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. , 1995, International archives of allergy and immunology.

[16]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[17]  C. March,et al.  Identification of a ligand for the c-kit proto-oncogene , 1990, Cell.

[18]  S. Nishikawa,et al.  Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.

[19]  P. Leder,et al.  The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus , 1990, Cell.

[20]  S. Nishikawa,et al.  Interspecies molecular chimeras of kit help define the binding site of the stem cell factor , 1993, Molecular and cellular biology.

[21]  Inder M. Verma,et al.  Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus , 1986, Nature.

[22]  Y. Matsuzawa,et al.  Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. , 1994, Blood.

[23]  K. Nocka,et al.  The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase. , 1990, Science.

[24]  I. Lax,et al.  Kit Receptor Dimerization Is Driven by Bivalent Binding of Stem Cell Factor* , 1997, The Journal of Biological Chemistry.

[25]  M. Roussel,et al.  Transforming potential of the c-fms proto-oncogene (CSF-1 receptor) , 1987, Nature.

[26]  Y. Matsuzawa,et al.  Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase (*) , 1996, The Journal of Biological Chemistry.

[27]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[28]  J. Ihle,et al.  Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand , 1993, Molecular and cellular biology.

[29]  A. Ullrich,et al.  Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site. , 1995, Oncogene.

[30]  S. Nagata,et al.  pEF-BOS, a powerful mammalian expression vector. , 1990, Nucleic acids research.

[31]  M. Greene,et al.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.

[33]  S. Lev,et al.  A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses. , 1992, Journal of Biological Chemistry.

[34]  A. Ullrich,et al.  Growth factor signaling by receptor tyrosine kinases , 1992, Neuron.

[35]  T. Kondo,et al.  Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. , 1996, Blood.

[36]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[37]  Alastair,et al.  Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. , 1991, The EMBO journal.

[38]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[39]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[41]  J. Pierce,et al.  Oncogenic activation of the αPDGFR defines a domain that negatively regulates receptor dimerization , 1997, Oncogene.

[42]  S. Majumder,et al.  c-kit protein, a transmembrane kinase: identification in tissues and characterization , 1988, Molecular and cellular biology.

[43]  Y. Yarden,et al.  Structural Aspects of Receptor Dimerization , 1995 .

[44]  Y. Nishimune,et al.  Mast cell number in the skin of heterozygotes reflects the molecular nature of c-kit mutation. , 1993, Blood.

[45]  David A. Williams,et al.  Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.

[46]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[47]  M. Eisenstein,et al.  The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction , 1995, Cell.

[48]  A. Ullrich,et al.  Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts. , 1988, The EMBO journal.

[49]  P. Leder,et al.  The kit ligand: A cell surface molecule altered in steel mutant fibroblasts , 1990, Cell.

[50]  Ursula Klingmüller,et al.  Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.

[51]  A. Reith,et al.  W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. , 1990, Genes & development.

[52]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[53]  T. Pawson,et al.  The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor , 1991, Molecular and cellular biology.

[54]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[55]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[56]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Y. Matsuzawa,et al.  Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. , 1996, Blood.